Immunovant (IMVT) Stock Forecast & Price Target

Compare

839 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMVT Analyst Ratings

Strong Buy

8 Buy

2 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Immunovant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMVT Stock 12 Month Forecast

Average Price Target

$41.67

▲(162.74%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $41.67 with a high forecast of $58.00 and a low forecast of $18.00. The average price target represents a 162.74% change from the last price of $15.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","59":"$59","25.25":"$25.3","36.5":"$36.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25.25,36.5,47.75,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,18.686153846153847,21.962307692307693,25.23846153846154,28.514615384615386,31.790769230769232,35.066923076923075,38.34307692307692,41.61923076923077,44.895384615384614,48.17153846153846,51.44769230769231,54.723846153846154,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,17.43,19.45,21.47,23.490000000000002,25.509999999999998,27.53,29.55,31.57,33.59,35.61,37.629999999999995,39.650000000000006,{"y":41.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.60923076923077,15.808461538461538,16.00769230769231,16.206923076923076,16.406153846153845,16.605384615384615,16.804615384615385,17.003846153846155,17.203076923076924,17.40230769230769,17.60153846153846,17.80076923076923,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.39,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$41.67

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian ChengJ.P. Morgan

J.P. Morgan

$40

Buy

152.21%

Upside

Reiterated

06/13/25

J.P. Morgan Sticks to Its Buy Rating for Immunovant (IMVT)

Thomas SmithLeerink Partners

Leerink Partners

$52

Buy

227.87%

Upside

Reiterated

05/30/25

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Dexcom (NASDAQ: DXCM) and Immunovant (NASDAQ: IMVT)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$51→$35

Buy

120.68%

Upside

Reiterated

05/30/25

Immunovant's Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position

Sam SlutskyLifeSci Capital

LifeSci Capital

$50

Buy

215.26%

Upside

Reiterated

05/30/25

Immunovant's Promising Clinical Trials and Strategic Drug Focus Justify Buy Rating

Derek ArchilaWells Fargo

Wells Fargo

$45

Buy

183.73%

Upside

Reiterated

05/29/25

Immunovant's Strategic Developments and Financial Strength Justify Buy Rating

Jason GerberryBank of America Securities

Bank of America Securities

$33

Buy

108.07%

Upside

Reiterated

05/29/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)

Eddie HickmanGuggenheim

Guggenheim

$44

Buy

177.43%

Upside

Reiterated

05/29/25

Guggenheim Reaffirms Their Buy Rating on Immunovant (IMVT)

Dennis DingJefferies

Jefferies

$20→$18

Hold

13.49%

Upside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Unknown AnalystUBS

Not Ranked

UBS

―

Hold

―

Downgraded

04/22/25

UBS downgrades Immunovant (IMVT) to NeutralUBS analyst Colin Bristow downgraded Immunovant (NASDAQ: IMVT) from Buy to Neutral with a price target of $17.00 (from $38.00).

Samantha SemenkowCiti

Citi

$58

Buy

265.70%

Upside

Reiterated

04/16/25

Analysts' Top Healthcare Picks: Allogene Therapeutics (ALLO), Immunovant (IMVT)

Leland GershellOppenheimer

Oppenheimer

$54

Buy

240.48%

Upside

Reiterated

03/20/25

Oppenheimer reiterates Outperform Rating on Immunovant (IMVT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT).

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$58→$61

Buy

284.62%

Upside

Reiterated

03/20/25

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

Yasmeen RahimiPiper Sandler

Piper Sandler

$57

Buy

259.39%

Upside

Reiterated

02/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunovant (NASDAQ: IMVT), Summit Therapeutics (NASDAQ: SMMT) and Outset Medical (NASDAQ: OM)

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Downgraded

01/03/25

Immunovant downgraded to Peer Perform from Outperform at Wolfe ResearchImmunovant downgraded to Peer Perform from Outperform at Wolfe Research

Danielle BrillRaymond James

Raymond James

$36

Buy

126.99%

Upside

Initiated

10/10/24

Immunovant resumed with an Outperform at Raymond JamesImmunovant resumed with an Outperform at Raymond James

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian ChengJ.P. Morgan

J.P. Morgan

$40

Buy

152.21%

Upside

Reiterated

06/13/25

J.P. Morgan Sticks to Its Buy Rating for Immunovant (IMVT)

Thomas SmithLeerink Partners

Leerink Partners

$52

Buy

227.87%

Upside

Reiterated

05/30/25

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Dexcom (NASDAQ: DXCM) and Immunovant (NASDAQ: IMVT)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$51→$35

Buy

120.68%

Upside

Reiterated

05/30/25

Immunovant's Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position

Sam SlutskyLifeSci Capital

LifeSci Capital

$50

Buy

215.26%

Upside

Reiterated

05/30/25

Immunovant's Promising Clinical Trials and Strategic Drug Focus Justify Buy Rating

Derek ArchilaWells Fargo

Wells Fargo

$45

Buy

183.73%

Upside

Reiterated

05/29/25

Immunovant's Strategic Developments and Financial Strength Justify Buy Rating

Jason GerberryBank of America Securities

Bank of America Securities

$33

Buy

108.07%

Upside

Reiterated

05/29/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV)

Eddie HickmanGuggenheim

Guggenheim

$44

Buy

177.43%

Upside

Reiterated

05/29/25

Guggenheim Reaffirms Their Buy Rating on Immunovant (IMVT)

Dennis DingJefferies

Jefferies

$20→$18

Hold

13.49%

Upside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Unknown AnalystUBS

Not Ranked

UBS

―

Hold

―

Downgraded

04/22/25

UBS downgrades Immunovant (IMVT) to NeutralUBS analyst Colin Bristow downgraded Immunovant (NASDAQ: IMVT) from Buy to Neutral with a price target of $17.00 (from $38.00).

Samantha SemenkowCiti

Citi

$58

Buy

265.70%

Upside

Reiterated

04/16/25

Analysts' Top Healthcare Picks: Allogene Therapeutics (ALLO), Immunovant (IMVT)

Leland GershellOppenheimer

Oppenheimer

$54

Buy

240.48%

Upside

Reiterated

03/20/25

Oppenheimer reiterates Outperform Rating on Immunovant (IMVT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT).

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$58→$61

Buy

284.62%

Upside

Reiterated

03/20/25

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

Yasmeen RahimiPiper Sandler

Piper Sandler

$57

Buy

259.39%

Upside

Reiterated

02/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunovant (NASDAQ: IMVT), Summit Therapeutics (NASDAQ: SMMT) and Outset Medical (NASDAQ: OM)

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Downgraded

01/03/25

Immunovant downgraded to Peer Perform from Outperform at Wolfe ResearchImmunovant downgraded to Peer Perform from Outperform at Wolfe Research

Danielle BrillRaymond James

Raymond James

$36

Buy

126.99%

Upside

Initiated

10/10/24

Immunovant resumed with an Outperform at Raymond JamesImmunovant resumed with an Outperform at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

1 Month

xxx

Success Rate

20/37 ratings generated profit

Average Return

+3.94%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.05% of your transactions generating a profit, with an average return of +3.94% per trade.

3 Months

xxx

Success Rate

12/19 ratings generated profit

Average Return

+16.64%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +16.64% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

9/19 ratings generated profit

Average Return

+49.92%

reiterated a buy rating 23 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +49.92% per trade.

2 Years

xxx

Success Rate

7/18 ratings generated profit

Average Return

+68.06%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 38.89% of your transactions generating a profit, with an average return of +68.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMVT has received 12 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is 41.67.

Each month's total comprises the sum of three months' worth of ratings.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.70 with a range of -$0.78 to -$0.62. The previous quarter’s EPS was -$0.64. IMVT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year IMVT has Outperformed its overall industry.

No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.79% of the time in the same period. In the last calendar year IMVT has Preformed in-line its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunovant, Inc.’s 12-month average price target is 41.67.

What is IMVT’s upside potential, based on the analysts’ average price target?

Immunovant, Inc. has 162.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMVT a Buy, Sell or Hold?

Immunovant, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.

What is Immunovant, Inc.’s price target?

The average price target for Immunovant, Inc. is 41.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $18.00. The average price target represents 162.74% Increase from the current price of $15.86.

What do analysts say about Immunovant, Inc.?

Immunovant, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of IMVT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Immunovant (IMVT) Stock Forecast & Price Target

IMVT Analyst Ratings

IMVT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunovant

IMVT Analyst Recommendation Trends

IMVT Financial Forecast

IMVT Earnings Forecast

IMVT Sales Forecast

IMVT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts